Clinical trials: Pain, Abdominal
Helicobacter Pylori Infection, Gastric Ulcer
Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects
The primary objective is to obtain stool samples from post-therapy subjects already undergoing evaluation for an H. pylori infection by upper esophagogastroduodenoscopy (EGD) and gastric biopsy.
- Conditions
- Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain
- Trial name
- NCT03060733
- Testing
- Post-Therapy
- Where
- 5 sites in United States, Italy
- Volunteers
- 13 people
- Sponsor
- DiaSorin Inc.
Inguinal Hernia
Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair
The primary objective of this study was to determine the appropriate dose of SKY0402 for the management of postoperative pain following inguinal hernia repair.
- Trial name
- NCT01203644
- Testing
- SKY0402, Bupivacaine HCl
- Volunteers
- 76 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Analgesia
Extended Delivery of Bupivacaine Study in Herniorrhaphy
This is a phase 4, randomized, open-label study of the efficacy, safety, and pharmacokinetics of bupivacaine administered as liposomal bupivacaine or continuous infusion via elastomeric pump following unilateral open inguinal…
- Trial name
- NCT04102267
- Testing
- Bupivacaine liposome injectable suspension, Bupivacaine HCl without epinephrine via continuous infusion
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Heron Therapeutics
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Congenital Sucrase-isomaltase Deficiency (CSID)
Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Congenital sucrose-isomaltase deficiency (CSID) is a rare, genetic disease in which mutations in the sucrose-isomaltase (SI) gene cause digestion problems of sucrose resulting in diarrhea and abdominal pain.
- Trial name
- CSID GPS (NCT01914003)
- Where
- 19 sites in United States
- Volunteers
- 53 people
- Sponsor
- QOL Medical, LLC
Hernia, Inguinal, Hernia, Ventral
AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair
The objective of this study is to assess pain that occurs following hernia repair that is related to mesh fixation. The study is designed to see if there is any difference in pain after surgery between absorbable and permanent…
- Trial name
- NCT00749268
- Testing
- AbsorbaTack, ProTack
- Where
- 2 sites in United States
- Volunteers
- 216 people
- Sponsor
- Medtronic - MITG
Pain
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
The primary objective is to evaluate the analgesic efficacy and safety of IV YZJ-4729 Tartrate Injection in patients with acute postoperative pain following abdominal surgery.
- Trial name
- NCT06890533
- Testing
- Experimental: YZJ-4729, Active Comparator: Morphine
- Where
- 49 sites in China
- Volunteers
- 560 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Abdominal Pain
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or…
- Trial name
- NCT02242305
- Testing
- Hyoscine Butylbromide - Tablet, Hyoscine Butylbromide - Capsule
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Functional Bowel Disorder
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and…
- Trial name
- NCT05175131
- Testing
- Mebeverine+Simethicone, Mebeverine, Simethicone
- Where
- Russia
- Volunteers
- 465 people
- Sponsor
- Abbott
Postsurgical Pain
Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations
Neospastil (ketorolac tromethamine / pitofenone hydrochloride / fenpiverinium bromide fixed-dose combination) in a form of solution for injections and film-coated tablets has been studied as a treatment for pain after surgical…
- Trial name
- NCT05607641
- Testing
- Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets, Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets, Neospastil, solution for injection then Neospastil, film-coated tablets
- Where
- 14 sites in Ukraine
- Volunteers
- 424 people
- Sponsor
- Darnitsa Pharmaceutical Company
Moderate to Severe Acute Postoperative Pain
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery
This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for postoperative pain management in abdominal surgery.
- Trial name
- NCT07311369
- Testing
- HL-1186
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Abdominal Pain/Gastrointestinal Issues, Lower Respiratory System Conditions
Clinic Waiting Room-based Study of Swahili Language Artificial Intelligence-driven Symptom Assessments in Tanzanian Primary Health Care Facilities
This study will evaluate the accuracy of the condition suggestions and urgency advice of the Swahili language Ada symptom assessment application (SAA), when symptoms are input by a lay-person user and a medical professional…
- Conditions
- Abdominal Pain/Gastrointestinal Issues, Lower Respiratory System Conditions, Upper Respiratory System Conditions, Mental Health Conditions
- Trial name
- AFYA (NCT04958577)
- Testing
- Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)
- Where
- Tanzania
- Volunteers
- 109 people
- Sponsor
- Ada Health GmbH
Pain
A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.
The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with placebo and morphine in patients with acute postoperative pain following abdominal surgery
- Trial name
- NCT04766463
- Testing
- SHR8554 Injection, Morphine
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hernia, Inguinal
Strattice in Repair of Inguinal Hernias
This is a prospective, randomized, controlled, third-party blinded, multicenter, interventional evaluation of inguinal hernia repair comparing Strattice to light weight polypropylene mesh.
- Trial name
- RING (NCT00681291)
- Testing
- Inguinal hernia repair with Ultrapro, Inguinal hernia repair with Strattice
- Where
- 8 sites in United States
- Volunteers
- 172 people
- Sponsor
- LifeCell
Symptomatic Gastroesophageal Reflux Disease (sGERD)
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
This study compares 4 weeks of treatment with Esomeprazole 20 mg once daily to Placebo in the treatment of Upper Abdominal Pain in patients with Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Trial name
- NCT00626535
- Testing
- Esomeprazole
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Fabry Disease
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age…
- Trial name
- PERIDOT (NCT05206773)
- Testing
- Venglustat (GZ402671)
- Where
- 50 sites in United States, Argentina and 19 more
- Volunteers
- 122 people
- Sponsor
- Sanofi
Postoperative Pain, Inguinal Hernia
Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy
The purpose of this study is to determine whether the CollaRx Bupivacaine implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after herniorrhaphy.
- Trial name
- NCT00626886
- Testing
- Bupivacaine Collagen Sponge
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Innocoll
Digestive Disease, Gut Health
Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes
The study team is conducting a consumer-driven, decentralized clinical research study to assess the impact of the consumer-grade probiotic supplement, iVS-1, on adults with moderate to severe gastrointestinal discomfort.
- Trial name
- NCT07408518
- Testing
- Probiotic
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Synbiotic Health
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.